Pre-market hot trades in US stocks: CIM Commercial Trust up 8.06% pre-market; Kustom ENT down 8.03% pre-market

Pre-market Hot Trades in US Stocks

CIM Commercial Trust is up 8.06% in pre-market trading. Based on recent key news:

1. On August 12, Creative Media & Community Trust announced that it will release its Q2 2026 financial report on August 14 and hold a conference call to discuss financial performance. This news has sparked market interest in the company's performance, driving the stock price up. Source: Business Wire

2. On August 12, Creative Media & Community Trust plans to conduct a 1-for-10 reverse stock split and sell its loan department to address first-quarter losses. This move is seen as part of the company's restructuring efforts, boosting investor confidence. Source: Business Wire

3. On August 12, there are concerns in the market regarding Creative Media & Community Trust's office real estate business. Despite the company's efforts to improve its financial situation, it still faces challenges. Source: Business Wire The real estate industry is under restructuring pressure, with significant cash flow issues.

Kustom ENT is down 8.03% in pre-market trading. Based on recent key news:

1. On August 13, the U.S. Securities and Exchange Commission launched an investigation into Kustom ENT, raising investor concerns. The investigation involves the accuracy and compliance of the company's financial statements, increasing regulatory risks and leading to a sharp decline in stock price.

2. On August 12, the quarterly financial report released by the company showed earnings below expectations. Although revenue increased, net profit declined, resulting in a negative market reaction and a drop in stock price.

3. On August 11, major analysts downgraded their ratings on Kustom ENT. Analysts believe there is uncertainty regarding the company's future profitability and advised investors to be cautious, further pressuring the stock price. Recent market volatility has been significant, and investors need to pay attention to risks.

Top Gainers in Pre-market US Stocks

Capricor Therapeutics is up 88.60% in pre-market trading. Based on recent key news:

1. On August 14, Capricor Therapeutics reported a net loss of $40.7 million for Q2, with an adjusted loss per share of $0.70 and zero revenue. Cash and cash equivalents decreased from $318.1 million on June 30 to $237.9 million. The stock price fell 82.6% in Q2 and is down 85.5% year-to-date. This financial performance has heightened market concerns about the company's future profitability.

2. On August 14, Capricor Therapeutics was accused of violating blinding and protocol in the HOPE-3 trial and creating a statistical analysis plan the day before data unblinding. This legal lawsuit increases the legal risks faced by the company, impacting investor confidence

3. On August 14, Capricor Therapeutics' ongoing discussions with the FDA led to the company's failure to hold a Q&A session, increasing market uncertainty regarding its regulatory approval progress. The company stated it would submit updated data for FDA review as soon as possible, and investors are looking forward to positive updates in the future. The biotechnology industry has recently faced regulatory challenges.

Akanda rose 87.23% in pre-market trading. Based on recent key news:

1. On August 13, Akanda Corporation released new content, emphasizing that its stock price had fallen 94.80% over the past year and was nearing its annual low. This information may trigger market attention on its future performance, leading to stock price volatility. Source: Newsfile

2. On August 14, Benzinga Pro data showed that Akanda's stock price closed at $5.01 during regular trading hours, down 7.05%. This negative trend may prompt investors to seek rebound opportunities in pre-market trading. Source: Benzinga

3. On August 14, Benzinga's Edge Stock Rankings indicated that Akanda's stock exhibited a negative price trend across all time frames, potentially exacerbating market concerns about its future performance. Source: Benzinga Market doubts about Akanda's future performance need attention.

China Su Xuan Tang Pharmaceutical rose 45.45% in pre-market trading. Based on recent key news:

1. On August 11, China Su Xuan Tang Pharmaceutical announced a 1-for-80 reverse stock split to meet Nasdaq's minimum bid requirements. This move aims to boost the stock price, restore market confidence, and drive the stock price up.

2. On August 11, the company conducted a multi-million dollar direct offering in early 2026 and attempted to integrate AI analysis into its R&D pipeline. This move demonstrates the company's proactive efforts in technological innovation, attracting investor attention.

3. No other significant news recently. The traditional Chinese medicine industry faces challenges and needs to pay attention to policy changes